Teicoplanin plus pefloxacine versus teicoplanin plus netilmicin in empiric therapy of febrile patients with cancer and neutropenia. A randomized study of two once daily regimens in patients with previously inserted catheters.
In a comparative randomized trial, teicoplanin 5 mg/kg plus either netilmicin 5 mg/kg or pefloxacine 10 mg/kg was administered in a once daily empiric therapy to 40 cancer patients with fever and neutropenia after cytotoxic chemotherapy. Both regimens were analyzed with respect to the localisation of the underlying disease, catheter presence and agents isolated from blood culture. The cure and improvement rate were 80% (teicoplanin plus netilmicin) and 85% (teicoplanin plus pefloxacin), with no statistically significant difference between the groups. Teicoplanin with either an aminoglycoside or a quinolone administered once daily seems to be a suitable approach in empiric therapy for fever in neutropenia and may prevent catheter insertion in cancer patients.
Studená
M
M
National Cancer Institute and Postgraduate Medical School, Bratislava, Slovakia.
Hlavácová
E
E
Hel'pianska
L
L
Vonkomerová
A
A
Lacka
J
J
Studená
V
V
Kukucková
E
E
Kollár
T
T
Pichna
P
P
Sálek
T
T
D000328:Adult; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005334:Fever / Q000188:drug therapy*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications; D008297:Male; D009369:Neoplasms / Q000150:complications; D009428:Netilmicin / Q000494:pharmacology*; D009503:Neutropenia / Q000188:drug therapy*; D015366:Pefloxacin / Q000627:therapeutic use*; D017334:Teicoplanin / Q000627:therapeutic use*
D015366:Pefloxacin; D009428:Netilmicin; D017334:Teicoplanin